Rafferty Asset Management
MLYS icon

Rafferty Asset Management’s Mineralys Therapeutics MLYS Stock Holding History

Rafferty Asset Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.11M Sell
78,186
-16,172
-17% -$444K ﹤0.01% 630
2026
Q1 		$2.56M Sell
94,358
-33,559
-26% -$984K 0.01% 558
2025
Q4 		$4.64M Buy
127,917
+96,232
+304% +$3.86M 0.02% 445
2025
Q3 		$1.2M Sell
31,685
-25,690
-45% -$556K ﹤0.01% 756
2025
Q2 		$776K Buy
+57,375
New +$831K ﹤0.01% 800

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Rafferty Asset Management's MLYS Position: Q2 2026 in Review

Rafferty Asset Management reduced its Mineralys Therapeutics (MLYS) stake by 17% in Q2 2026, selling an estimated $444K and leaving 78,186 shares worth $2.11M. The position accounts for ﹤0.01% of the portfolio, ranked #630.

Rafferty Asset Management first reported a position in MLYS in Q2 2025 and has held it in 5 quarters since. The position peaked at $4.64M in Q4 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Rafferty Asset Management held 78,186 shares of Mineralys Therapeutics worth $2.11M as of Q2 2026.
  • Rafferty Asset Management sold 16,172 Mineralys Therapeutics shares in Q2 2026, an estimated $444K.
  • Mineralys Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #630 holding.
  • Rafferty Asset Management first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Rafferty Asset Management's Mineralys Therapeutics position peaked at $4.64M in Q4 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.